ArticleJournal of nanobiotechnology2025
Plain DNA and cationic aromatics: a platform to simplify carrier-free delivery systems.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AIEgen-mediated integration of plain DNA and hydrophobic compounds enabling three-in-one nanosystems for carrier-free delivery.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
DNA nanotechnology offers a powerful alternative in biomedical areas yet a simple and general strategy to engineer DNA-based nanomedicine bearing high and adjustable drug-loading capacity and stability remains challenging. Herein, we report that it is a ubiquitous property for plain DNA (except for guanine-rich sequences) to assemble with the widely used anticancer drug, doxorubicin hydrochloride (DOX), into well-defined nanospheres via thermal annealing, which circumvents additional adjuvants (e.g., metal ions) or chemical modifications of DNA (e.g., hydrophobic conjugation). Experimental results and molecular dynamics simulation reveal that shape remolding is a result of heat-promoted intra-particle interactions. We demonstrate that the nanospheres display high DOX-loading capacity and feasible size controllability, and the generality of this approach is also established with diverse functional cationic aromatics (drugs, fluorescent dyes and aggregation-induced emission luminogens). Finally, we construct a carrier-free nanomedicine by assembling DOX with a therapeutic antisense oligonucleotide, and the combined therapeutic performance is demonstrated in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.